ReceptoPharm  
Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Overview
» Research Platform
» R&D Pipeline
» Published Research
» Licensing
 
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
 
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More

Drug Development

ReceptoPharm is an innovative biopharmaceutical drug discovery company developing proprietary therapeutic protein products for the billion-dollar biologics market. The Company has two leading products: RPI-MN and RPI-78M.

RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and Human Immunodeficiency Virus (HIV). It is being developed first for the treatment of HIV.

RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS).

 

RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to ReceptoPharm, the drugs are created through a process of chemical modification.

RPI-MN and RPI-78M possess several desirable properties as drugs:

  • They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
  • They display no serious adverse side effects following years of investigations in humans and animals.
  • They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
  • They are easy to administer.
  • RPI-78M can be administered orally -- a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.
Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
 
E-Alerts
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name:
Email:
NPC